Topiramate add-on for drug-resistant partial epilepsy
Authors:
- N JetteNJN Jette
- K HemmingKHK Hemming
- Jl HuttonJHJl Hutton
- Ag MarsonAMAg Marson
- 22 July 2002
- reference entry
- Published by Wiley
- No. 2,p. CD001417
Abstract
The majority of epileptic patients have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug-resistant partial epilepsy. To evaluate the efficacy and tolerability of topiramate when used as an add-on treatment in patients with drug resistant partial epilepsy. (a) The Cochrane Library (1999 Issue 1); (b) The controlled trial register of the Cochrane Epilepsy Group; (c) Johnson and Johnson, makers of topiramate; (d) Experts in the field. Randomized placebo controlled add-on trials of topiramate in patients with drug resistant epilepsy. Two reviewers independently selected trials for inclusion and extracted the relevant data. The following outcomes were assessed: (a) 50% or greater reduction in seizure frequency; (b) treatment withdrawal (any reason); (c) side effects. Primary analyses were intention to treat. Summary odds ratios (OR) were estimated for each outcome. Dose response was evaluated in regression models. Six trials were included representing 743 randomized patients. Overall OR (95% CIs) for 50% or greater reduction in seizure frequency compared to placebo 4.06 (2.86-5.78). Dose regression analysis shows increasing efficacy with increasing dose, but found no advantage for doses over 400 mg per day. Global effectiveness: treatment withdrawal OR (95% CIs) compared to placebo 2.57 (1.65-4.00). Side effects: OR (99% CIs)compared to placebo, dizziness 1.99 (1.20-3.29); fatigue 2.52 (1. 47-4.32); nausea 2.84 (1.36-5.93); somnolence 2.89 (1.72-4.85) and 'thinking abnormally' 3.71 (2.02-6.80) were significantly associated with topiramate. Topiramate has efficacy as an add-on treatment in patients with drug resistant partial epilepsy. However, trials reviewed were of relatively short duration, and provide no evidence for the long term efficacy of topiramate. Results cannot be extrapolated to monotherapy or patients with other epilepsy types.Keywords
This publication has 26 references indexed in Scilit:
- Low-dose topiramate in adults with treatment-resistant partial-onset seizuresActa Neurologica Scandinavica, 2002
- Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)Epilepsy Research, 2002
- A Multicenter, Randomized Clinical Study to Evaluate the Effect on Cognitive Function of Topiramate Compared with Valproate as Add‐On Therapy to Carbamazepine in Patients with Partial‐Onset SeizuresEpilepsia, 2000
- A Double‐Blind, Placebo‐Controlled Study of Topiramate in Adult Patients with Refractory Partial EpilepsyEpilepsia, 2000
- Topiramate in Medically Intractable Partial Epilepsies: Double‐Blind Placebo‐Controlled Randomized Parallel Group TrialEpilepsia, 1999
- A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in childrenNeurology, 1999
- Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsyEpilepsy Research, 1996
- Double‐Blind, Placebo‐Controlled Trial of Topiramate (600 mg Daily) for the Treatment of Refractory Partial EpilepsyEpilepsia, 1996
- Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosagesNeurology, 1996
- Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosagesNeurology, 1996